Clinical trial
A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response
NCT04550494 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- April 26, 2021
- Completion date
- July 27, 2027
- Enrollment
- 29 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
anatomic stage iii breast cancer ajcc v8, anatomic stage iv breast cancer ajcc v8, castration-resistant prostate carcinoma, clinical stage iii gastric cancer ajcc v8, clinical stage iv gastric cancer ajcc v8, her2-positive breast carcinoma, locally advanced breast carcinoma, locally advanced gastric carcinoma, locally advanced malignant solid neoplasm, locally advanced ovarian carcinoma, locally advanced pancreatic carcinoma, locally advanced prostate carcinoma, metastatic breast carcinoma, metastatic gastric carcinoma, metastatic malignant solid neoplasm, metastatic ovarian carcinoma, metastatic pancreatic carcinoma, metastatic prostate carcinoma, platinum-sensitive ovarian carcinoma, recurrent breast carcinoma, recurrent gastric carcinoma, recurrent ovarian carcinoma, recurrent pancreatic carcinoma, recurrent prostate carcinoma, stage ii pancreatic cancer ajcc v8, stage iii ovarian cancer ajcc v8, stage iii pancreatic cancer ajcc v8, stage iii prostate cancer ajcc v8, stage iv ovarian cancer ajcc v8, stage iv pancreatic cancer ajcc v8, stage iv prostate cancer ajcc v8